SEC Comment Letter 0000000000-24-004750 to LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Date: April 29, 2024 · CIK: 0001335105 · Accession: 0000000000-24-004750
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278874
Letter
United States securities and exchange commission logo April 29, 2024 Bas van der Baan Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 Re:Lixte Biotechnology Holdings, Inc. Registration Statement on Form S-3 Filed April 23, 2024 File No. 333-278874 Dear Bas van der Baan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Ficksman, Esq.
Show Raw Text
United States securities and exchange commission logo
April 29, 2024
Bas van der Baan
Chief Executive Officer
Lixte Biotechnology Holdings, Inc.
680 East Colorado Boulevard, Suite 180
Pasadena, California 91101
Re:Lixte Biotechnology Holdings, Inc.
Registration Statement on Form S-3
Filed April 23, 2024
File No. 333-278874
Dear Bas van der Baan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David Ficksman, Esq.